CA2852942C - Method of treating or reducing efp - Google Patents

Method of treating or reducing efp Download PDF

Info

Publication number
CA2852942C
CA2852942C CA2852942A CA2852942A CA2852942C CA 2852942 C CA2852942 C CA 2852942C CA 2852942 A CA2852942 A CA 2852942A CA 2852942 A CA2852942 A CA 2852942A CA 2852942 C CA2852942 C CA 2852942C
Authority
CA
Canada
Prior art keywords
collagenase
administered
injection
efp
injections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2852942A
Other languages
English (en)
French (fr)
Other versions
CA2852942A1 (en
Inventor
Susan G. Emeigh Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auxilium International Holdings Inc
Original Assignee
Auxilium International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium International Holdings Inc filed Critical Auxilium International Holdings Inc
Publication of CA2852942A1 publication Critical patent/CA2852942A1/en
Application granted granted Critical
Publication of CA2852942C publication Critical patent/CA2852942C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2852942A 2011-10-21 2012-10-19 Method of treating or reducing efp Active CA2852942C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
US61/549,863 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Publications (2)

Publication Number Publication Date
CA2852942A1 CA2852942A1 (en) 2013-04-25
CA2852942C true CA2852942C (en) 2023-01-10

Family

ID=48141393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2852942A Active CA2852942C (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Country Status (14)

Country Link
US (2) US20140335072A1 (enExample)
EP (2) EP2768523B1 (enExample)
JP (5) JP2014530873A (enExample)
AU (6) AU2012325941A1 (enExample)
BR (1) BR112014009785B1 (enExample)
CA (1) CA2852942C (enExample)
DK (2) DK3581199T3 (enExample)
ES (2) ES2953560T3 (enExample)
FI (1) FI3581199T3 (enExample)
HU (2) HUE044650T2 (enExample)
MX (2) MX2014004792A (enExample)
PL (1) PL3581199T3 (enExample)
PT (2) PT3581199T (enExample)
WO (1) WO2013059619A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4276180B1 (en) 2012-01-12 2026-04-22 Endo Biologics Limited Clostridium histolyticum enzyme
CA2872227A1 (en) 2012-05-01 2013-11-07 Proteolease Ltd. Methods for extracting a tooth
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
IL327169A (en) 2017-03-01 2026-05-01 Endo Ventures Ltd A method for assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN121337429A (zh) 2018-07-23 2026-01-16 雷维尔美学公司 脂肪团处理系统和方法
MX2021000901A (es) * 2018-07-23 2021-06-18 Revelle Aesthetics Inc Sistema y metodos de tratamiento de celulitis.
WO2020058755A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法
CN114793417A (zh) 2019-09-06 2022-07-26 雷维尔美学公司 皮下脂肪团治疗系统和方法
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods
WO2022221525A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Culture of tumor infiltrating lymphocytes from tumor digest

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
WO2008101406A1 (en) * 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction

Also Published As

Publication number Publication date
BR112014009785B1 (pt) 2020-06-30
AU2020200763A1 (en) 2020-02-20
AU2012325941A1 (en) 2014-05-15
MX2014004792A (es) 2015-08-14
EP3581199B1 (en) 2023-05-31
HUE063599T2 (hu) 2024-01-28
EP2768523A4 (en) 2015-04-22
NZ759819A (en) 2020-11-27
BR112014009785A8 (pt) 2020-02-27
PT2768523T (pt) 2019-08-29
US20140335072A1 (en) 2014-11-13
NZ624057A (en) 2016-08-26
DK3581199T3 (da) 2023-09-04
HUE044650T2 (hu) 2019-11-28
PT3581199T (pt) 2023-08-31
WO2013059619A1 (en) 2013-04-25
JP2020158521A (ja) 2020-10-01
HK1201439A1 (en) 2015-09-04
NZ769098A (en) 2022-03-25
AU2020200763B2 (en) 2022-05-26
AU2022202987B2 (en) 2025-03-20
AU2016202026A1 (en) 2016-04-21
US20240216485A1 (en) 2024-07-04
JP2024123126A (ja) 2024-09-10
CA2852942A1 (en) 2013-04-25
AU2022202987A1 (en) 2022-05-26
JP7853845B2 (ja) 2026-04-30
ES2741476T3 (es) 2020-02-11
JP2022123073A (ja) 2022-08-23
NZ737403A (en) 2020-05-29
JP2014530873A (ja) 2014-11-20
PL3581199T3 (pl) 2023-09-11
NZ722722A (en) 2019-05-31
AU2017248451A1 (en) 2017-11-02
EP3581199A1 (en) 2019-12-18
AU2017248451B2 (en) 2019-11-14
JP2018027968A (ja) 2018-02-22
DK2768523T3 (da) 2019-07-22
BR112014009785A2 (pt) 2017-04-25
FI3581199T3 (fi) 2023-08-18
EP2768523A1 (en) 2014-08-27
ES2953560T3 (es) 2023-11-14
MX2019007779A (es) 2019-09-04
AU2025204462A1 (en) 2025-07-03
EP2768523B1 (en) 2019-05-22
MX392388B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
AU2022202987B2 (en) Method of treating or reducing efp
US10123959B2 (en) Methods for treating cellulite
CN101405023A (zh) 治疗脂肪团的方法
HK40020065B (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
HK40020065A (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
NZ624057B2 (en) Method of treating or reducing efp
HK1201439B (en) Method of treating or reducing efp
NZ737403B2 (en) Method of treating or reducing efp
NZ769098B2 (en) Method of treating or reducing efp
NZ722722B2 (en) Method of treating or reducing efp
NZ759819B2 (en) Method of treating or reducing efp
TW202138002A (zh) A型肉毒桿菌毒素複合物、其配製劑和使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140417

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240926

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240926

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908